| Literature DB >> 33413610 |
Daniel Ward1, Matthew Higgins2, Jody E Phelan2, Martin L Hibberd2, Susana Campino2, Taane G Clark3,4.
Abstract
During COVID-19, diagnostic serological tools and vaccines have been developed. To inform control activities in a post-vaccine surveillance setting, we have developed an online "immuno-analytics" resource that combines epitope, sequence, protein and SARS-CoV-2 mutation analysis. SARS-CoV-2 spike and nucleocapsid proteins are both vaccine and serological diagnostic targets. Using the tool, the nucleocapsid protein appears to be a sub-optimal target for use in serological platforms. Spike D614G (and nsp12 L314P) mutations were most frequent (> 86%), whilst spike A222V/L18F have recently increased. Also, Orf3a proteins may be a suitable target for serology. The tool can accessed from: http://genomics.lshtm.ac.uk/immuno (online); https://github.com/dan-ward-bio/COVID-immunoanalytics (source code).Entities:
Keywords: COVID; Cross-reactivity; Epitopes; Human-coronavirus; Immuno-informatics; Mutation; SARS-CoV-2; Surveillance
Mesh:
Substances:
Year: 2021 PMID: 33413610 PMCID: PMC7790334 DOI: 10.1186/s13073-020-00822-6
Source DB: PubMed Journal: Genome Med ISSN: 1756-994X Impact factor: 11.117